Fig. 2From: Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in SwedenIsavuconazole – cost-effectiveness acceptability curve from the probabilistic sensitivity analysis. QALY, quality-adjusted life-year; WTP Threshold, threshold of willingness to pay cost per QALYBack to article page